Customize
Quick Links
Specialties

Accreditation/Credit Designation

Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Acknowledgment of Commercial Support

This activity is supported by an educational grant from Celgene Corporation.

Oncology Briefings™: Treating Advanced NSCLC Without Actionable Mutations


Release Date: August 30, 2018
Expiration Date: August 30, 2019
Media: Internet - based

Activity Overview

This activity, Oncology Briefings™: Treating Advanced NSCLC Without Actionable Mutations, developed in Physicians’ Education Resource, LLC, (PER®) established Oncology Briefings™ legacy format, is an online interactive monograph that provides treatment strategies for patients with advanced non-small cell lung cancer (NSCLC) without actionable mutations. This presentation features a national thought leader, Thomas E. Stinchcombe, MD, who provides key insights.

Acknowledgement of Commercial Support

This activity is supported by an educational grant from Celgene Corporation.

 

Instructions for This Activity and Receiving Credit

  • You will need to login to participate in the activity.
  • Each presentation may contain an interactive question(s). You may move forward through the presentation; however, you may not go back to change answers or review videos/content until you finish the presentation.
  • At the end of the activity, “educational content/video files” will be available for your reference.
  • In order to receive a CME certificate, participants must complete the activity.
  • Complete the posttest and pass with a score of 70% or higher, complete the evaluation and then click on request for credit. Participants may immediately download a CME certificate upon completion of these steps.


Target Audience

This activity is directed toward oncology healthcare professionals who treat patients with lung cancer, including medical oncologists, radiology oncologists, and surgical oncologists. Fellows, nurses, nurse practitioners, pulmonologists, physician assistants, and other healthcare professionals involved in the management of patients with lung cancers are also invited to participate.

Educational Objectives

Upon completion of this activity, you should be better prepared to:

  • Discuss current and emerging strategies for the treatment of patients with advanced NSCLC without actionable oncogenic drivers in the frontline setting and beyond
  • Integrate emerging clinical data on systemic and immunotherapeutic combination treatment strategies into the paradigm for advanced lung cancer
  • Determine initial and subsequent therapeutic options for patients with lung cancer without actionable mutations
  • Identify and mitigate treatment-related adverse events in the overall management of patients with lung cancers

Faculty, Staff, and Planners' Disclosures

Faculty

Thomas E. Stinchcombe, MD
Professor of Medicine
Duke Cancer Institute
Durham, NC
 
 

Disclosure: Grant/Research Support: AstraZeneca, Genentech/Roche, Takeda (institution); Consultant: Takeda, Novartis, Genentech/Roche, AstraZeneca

The staff of PER® have no relevant financial relationships with commercial interests to disclose.

Disclosure Policy and Resolution of Conflicts of Interest

As a sponsor accredited by the ACCME, it is the policy of PER® to ensure fair balance, independence, objectivity, and scientific rigor in all of its CME activities. In compliance with ACCME guidelines, PER® requires everyone who is in a position to control the content of a CME activity to disclose all relevant financial relationships with commercial interests. The ACCME defines relevant financial relationships as financial relationships in any amount occurring within the past 12 months that create a conflict of interest (COI).

Additionally, PER® is required by ACCME to resolve all COI. PER® has identified and resolved all COI prior to the start of this activity by using a multistep process.
 

Off-Label Disclosure and Disclaimer

This CME activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME activity is for continuing medical and nursing education only, and is not meant to substitute for the independent clinical judgment of a physician or nurse relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty member, and do not reflect those of PER® or the company that provided commercial support for this activity.







Become a Member

Forgot Password?
Filter By